Gladice Wallraven

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande et al. · The Lancet Oncology · 2020 · 112 citations

Medicine, Immunology, Gynecology +6

Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma

Maurizio Ghisoli, Minal Barve, Robert Mennel et al. · Molecular Therapy · 2016 · 94 citations · Full text

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

Maurizio Ghisoli, Minal Barve, Reva Schneider et al. · Molecular Therapy · 2015 · 53 citations · Full text

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer

Rodney P. Rocconi, Bradley J. Monk, Adam Walter et al. · Gynecologic Oncology · 2021 · 35 citations

Radiation Oncology, Homologous Recombination Proficient, Cell Therapy +8

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

Rodney P. Rocconi, Erin Stevens, Justin Bottsford-Miller et al. · Cancer Gene Therapy · 2021 · 23 citations

Medicine, Cancer Management, Principle Study +7